Gilead Sciences, Inc. (NASDAQ:GILD) Position Decreased by Aviso Wealth Management

Aviso Wealth Management cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,421 shares of the biopharmaceutical company’s stock after selling 259 shares during the period. Aviso Wealth Management’s holdings in Gilead Sciences were worth $316,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in GILD. Kingsview Wealth Management LLC boosted its position in shares of Gilead Sciences by 8.9% in the 3rd quarter. Kingsview Wealth Management LLC now owns 19,923 shares of the biopharmaceutical company’s stock valued at $1,670,000 after purchasing an additional 1,628 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Gilead Sciences by 79.2% in the third quarter. Larson Financial Group LLC now owns 7,835 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 3,464 shares during the period. Independent Advisor Alliance raised its holdings in shares of Gilead Sciences by 1.2% during the third quarter. Independent Advisor Alliance now owns 23,730 shares of the biopharmaceutical company’s stock valued at $1,990,000 after acquiring an additional 270 shares during the period. Truvestments Capital LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $126,000. Finally, FMR LLC boosted its stake in Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Royal Bank of Canada raised their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Morgan Stanley lifted their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, March 11th. Piper Sandler increased their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.52.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 302,785 shares of company stock worth $30,503,250. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 1.1 %

GILD stock opened at $107.89 on Wednesday. The business’s 50-day simple moving average is $104.35 and its 200 day simple moving average is $94.36. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The company has a market cap of $134.36 billion, a PE ratio of 291.59, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.93%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.